PT  - JOURNAL ARTICLE
AU  - Wang, Michael
AU  - Faust, Marcus
AU  - Abbott, Scott
AU  - Patel, Vikrant
AU  - Chang, Eric
AU  - Clark, John I.
AU  - Stella, Nephi
AU  - Muchowski, Paul J.
TI  - A Cannabidiol/Terpene Formulation Increases Restorative Sleep in Insomniacs: A Double-Blind, Placebo-controlled, Randomized, Crossover Study
AID  - 10.1101/2023.06.03.23290932
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2023.06.03.23290932
4099  - http://medrxiv.org/content/early/2024/02/28/2023.06.03.23290932.short
4100  - http://medrxiv.org/content/early/2024/02/28/2023.06.03.23290932.full
AB  - Study Objectives Cannabidiol (CBD) is increasingly used as a health supplement, though few human studies have demonstrated benefits. The primary objective of this study was to evaluate the effects of an oral CBD-terpene formulation on sleep physiology in insomniacs.Methods In this double-blind, placebo-controlled, randomized clinical trial, 125 insomniacs received an oral administration of CBD (300 mg) and terpenes (1 mg each of linalool, myrcene, phytol, limonene, α-terpinene, α-terpineol, α-pinene, and β-caryophyllene) for ≥ four days/week over four weeks using a crossover design. The study medication was devoid of Δ9-Tetrahydrocannabinol (Δ9-THC). The primary outcome measure was the percentage of time participants spent in the combination of slow wave sleep (SWS) and rapid eye movement (REM) sleep stages, as measured by a wrist-worn sleep-tracking device.Results This CBD-terpene regimen significantly increased the mean nightly percentage of time participants spent in SWS + REM sleep compared to the placebo [mean (SEM), 1.28% (0.60%), 95% C.I. 0.09 to 2.46, P = 0.03]. More robust increases were observed in participants with low baseline SWS + REM sleep, as well as in day-sleepers. For select participants, the increase in SWS + REM sleep averaged as much as 48 min/night over a four-week treatment period. This treatment had no effect on total sleep time (TST), resting heart rate or heart rate variability, and no adverse events were reported.Conclusions Select CBD-terpene ratios may increase SWS + REM sleep, and have the potential to provide a safe and efficacious alternative to over-the-counter (OTC) sleep aids and commonly prescribed sleep medications.Current Knowledge/Study Rationale Physicians are increasingly asked by their patients regarding the merits of using CBD for insomnia and other ailments, but lack any rigorous clinical research to support recommending its use. The current study represents the first double-blind, placebo-controlled and randomized crossover clinical trial to investigate how an oral formulation of cannabidiol (CBD) and terpenes influences sleep physiology in insomniacs.Study Impact In contrast to many OTC sleep aids and commonly prescribed sleep medicines, the CBD-terpene formulation increased SWS and REM sleep, which are critical for the immune system, tissue regeneration, cognition and memory. These results, if confirmed in larger clinical trials, suggests that CBD might offer a promising alternative to other prescription sleep medications and OTC sleep aids.Competing Interest StatementMichael Wang, Marcus Faust, Scott Abbott, Vikrant Patel, Eric Chang and Dr. Paul Muchowski hold equity in Defined Research Inc., a for-profit company. Dr. John Clark and Dr. Nephi Stella are unpaid consultants who hold stock options for equity in Defined Research Inc. Funding for this study was provided by Defined Research, Inc.Clinical TrialClinicalTrials.gov Identifier: NCT05233761Funding StatementThis study was funded by Defined Research, Inc., a for-profit biotechnology company.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board Allendale Institutional Review Board, Lyme, Connecticut.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript